Inimmune
Monday, February 26, 2024
Royale
Immunology
Inimmune is a private clinical stage company dedicated to developing immuno-therapeutics. It is focused on advancing its Toll Like Receptor ligand portfolio as immunotherapeutics and vaccine adjuvants to be used alone or in combination to treat cancer, allergy, autoimmune disorders and infectious diseases. Our disruptive, disease modifying allergy therapy is making excellent progress in a phase I trial and our immuno-
oncology therapy will begin phase I enrollment in January 2024. The company, through its chemistry, formulation and immunology expertise has been awarded over $40 million in NIH-sponsored programs with leading U.S. based universities developing vaccines to treat a variety of conditions including infectious diseases and opioid addiction. In addition to our allergy and oncology phase I clinical trials, we expect to initiate an additional three clinical trials in the next 18 months.
State
Montana
Country
United States
Website
http://www.inimmune.com
CEO/Top Company Official
CEO: Alan Joslyn, PhD
Lead Product in Development
INI-2004 disease modifying product for allergy
INI-4001 immunotherapeutic for treatment of solid tunors
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
Four: INI-2004, INI-4001, opioid (fentanyl & heroin) vaccines, synthetic saponin + TLR4 agonist vaccine adjuvant
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}